VivoSeq
Oncology

Metastatic Solid Cancers

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Metastatic Solid Cancers is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

20/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Active, not recruiting1 · 20%
Recruiting1 · 20%
Withdrawn1 · 20%
Completed1 · 20%
Unknown status1 · 20%

Clinical Trials

Trial Activity

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
Active, not recruiting·IImmunityBio, Inc.·Phase 1·NCT04050709·16 enrolled
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06606990·40 enrolled
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Withdrawn·—·Phase 2·NCT03868423
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
Completed·UUniversity of Chicago·Phase 1·NCT02540876·12 enrolled
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers
Unknown status·KKorean Cancer Study Group·Phase 2·NCT04761744·48 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)